Member Info for Scharnhorst

Fantastic news for recent YGEN shareholders who weren't involved prior to the shocking placing which effectively wiped out former investors. Well done if you're in that happy place jamrock, but I suspect most long term holders will have lost money. Some will have clawed back some losses through the placing at 0.3p, but in the two years before the 2022 annus horribilis it was trading around 15p.

I don't pay attention to product reviews of the new MHC tests as they're likely to be submitted by shareholders with a vested financial interest. Who else would know they exist? Where is the evidence that they are being marketed to the wider public?

Given the brain-dead votes for consolidation and keeping spiv directors in a job. The YGEN evidence was there for all to see.

Some big decisions made today yet only 26% of shares were voted. Let's see what good the consolidation does. Until there is proof of meaningful sales and profits from new tests, I expect it to have a significant negative impact on the share price.

It beats me why 25% of shareholders actively voted for Lyn Rees to remain as one of our directors when he's performed so atrociously at YGEN. Turkeys voting for Christmas imo.

The state of the share price was due to absence of news on new tests, promised ‘shortly’ way back in January. As the problem wasn’t due to the low share price, artificially increasing the share price by consolidation won’t be the solution. They need to show increased revenue and profit. Note in the statement about the consolidation that it’s ‘we hope this’ and ‘we believe that.’ Just a lot of waffle from Reynolds the YGEN failure.

To be fair Penny was probably advised to RNS by the trained monkeys who read the bulletin boards at her PR outfit. I look forward to the day they are replaced by AI.

What they were supposed to be doing since January was getting news out SHORTLY on new products. Instead they're fannying about with little bits of housekeeping that may be good for shareholders or not. Quite possibly the latter given the antics of two of our directors at YGEN.
Where's the fricking beef?

Jamrock, you have it wrong on two counts. First, Lyn Rees did not leave YGEN. Remarkably he is still at the dog despite having shafted shareholders. It’s former chairman Adam Reynolds who stepped down after the rescue funding. As you’ve been told before we currently have two directors who were instrumental in the collapse of the YGEN share price.
Second, Penny didn’t appoint Lyn Rees. He was brought into the company at the same time as Penny by largest shareholder Mercia Asset Management.
Penny’s good but she seems a bit short on experience and too reliant on the failures Reynolds and Rees. Reynolds is always lurking in the background of their IMC presentations but the only two pearls of wisdom he has offered so far is that MHC share price declined in line with the Market at the interims, and the company is priced at cash at the finals. Not exactly genius material.

I'll be voting against the consolidation and also the approval to change the nominal value of the shares which requires 75% of shareholders to vote for it. The company shouldn't be consolidating until it can demonstrate the new products are performing. Until then the consolidation will simply put the share price on a coconut shy ready to be knocked down. I'll also be voting against reappointment of Lyn Rees. He took YGEN shareholders to the cleaners and looks like he is trying to do the same to us.

‘Investing Genius’ forgot about the diluting placed shares which just about double the market cap.

TWD got into bed with a pox ridden old goat. Arrival share price has declined from 35 dollars to 13 cents. It is running out of cash, the UK business is a busted flush and US operations are delayed again. They are late in reporting FY22. It won't make good reading.

Cash running out in May?

Not sure what you totally disagree with. This says to me they're still in the development phase
"The new product development timeline for an extended portfolio of wellness tests is on track"
I concede the quality of their communication is poor so it could mean anything to anyone. Maybe that's the point.

I'm only reading between the lines but the new products are still in the development phase according to the update so presumably they haven't been ready to go in store. Hopefully that changes pdq.

When you applaud them for having £7m in the bank, bear in mind they’ve raised £9m from shareholders over the past 4 years. There is no way they’re going to repeat last year’s LFT revenue. People aren’t buying as many tests otherwise December would have broken the July record and they would have said so. Covid worse in winter than summer and it was rife in December. Also they’re being undercut at Lloyds pharmacy by another supplier so that will affect sales.

JBongo, you can combine information in the interim results with the recent update to work out that covid revenue from August to December was similar to revenue during July ie. It has declined from about 6m in that month alone to about 1m a month. It’s not difficult.
The CEO certainly hasn’t been transparent about delays to the launch of the new tests. She hides behind the spin of their useless PR outfit Walbrook, hence bull like “the new timeline is on track.”

“imagine you have over 7m in the bank a turnover of 22m and a market capital of only 12m”

The markets look forward not back. That 22m turnover last year is not repeatable this year on LFT covid revenue alone, which the trading update confirmed has declined since the bumper month of July.
New products with proven demand are required. The board hasn’t been truthful on timelines and reasons for repeated delays. Taking those facts into account the current share price is understandable even if annoying.

The main problem is the launch of new products has been delayed again and they didn’t give a reason. That is shockingly bad communication, especially when they hyped the launch in last year’s interim statement.

As jyee7 pointed out, everything ace said contradicted the info in the update.

Good trading update. As expected covid tests are keeping us ticking over while we wait for the launch of wellness tests. I do take issue with the following though:
"The new product development timeline for an extended portfolio of wellness tests is on track"
It's as if we knew about the new development timeline. The truth is that the old development timeline bombed for reasons they haven't told us.

Did ace2326 read the update?